Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.

Current oncology (Toronto, Ont.) - 24 Feb 2022

Voutsadakis Ioannis A

Abstract excerpt

Background: Urothelial bladder carcinomas had traditionally been difficult to treat cancers, with high morbidity and mortality rates when invasive and metastatic. In recent years, immunotherapy with immune checkpoint inhibitors has improved outcomes in several cancers, including bladder carcinomas. Despite positive overall results, many bladder cancer patients do not respond to immunotherapies. Validated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Carcinoma, Transitional Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Mutation

Share to Prognosis

Share to Urinary Bladder

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 35323317
DOI: 10.3390/curroncol29030117
PMCID: PMC8947463

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Urothelial Bladder Carcinomas with High Tumor Mutation Burden Have a Better Prognosis and Targetable Molecular Defects beyond Immunotherapies.PMID 35323317Read ↗

Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer.Semantic proximity Read ↗

Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.Semantic proximity Read ↗

The Cancer Genome Atlas Project in Bladder Cancer.Semantic proximity Read ↗

Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.Semantic proximity Read ↗

Similar genetic profile in early and late stage urothelial tract cancer.Semantic proximity Read ↗

Advances in bladder cancer biology and therapy.Semantic proximity Read ↗

Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden.Semantic proximity Read ↗

Integrated Genomic and Single-Cell Analysis Reveals Heterogeneity, Prognosis, and Treatment Vulnerability in Urothelial Carcinoma.Semantic proximity Read ↗

New discoveries in the molecular landscape of bladder cancerSemantic proximity Read ↗

Novel Genetic Subtypes of Urothelial Carcinoma With Differential Outcomes on Immune Checkpoint Blockade.Semantic proximity Read ↗

Molecular Profiling of Bladder Adenocarcinoma Using a National Genomics RepositorySemantic proximity Read ↗

Mutation signatures to Pan-Cancer Atlas: Investigation of the genomic landscape of muscle-invasive bladder cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.